{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:58:12Z","timestamp":1785293892084,"version":"3.55.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.reth.2024.12.007","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T15:47:59Z","timestamp":1735660079000},"page":"262-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Viral-based gene therapy clinical trials for immune deficiencies and blood disorders from 2013 until 2023 - an overview"],"prefix":"10.1016","volume":"28","author":[{"given":"Shirin","family":"Eshghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Mousakhan Bakhtiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Behfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Naji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashin","family":"Mohseni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1616-9404","authenticated-orcid":false,"given":"Zohreh","family":"Saltanatpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Ali","family":"Hamidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reth.2024.12.007_bib1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41434-019-0093-4","article-title":"Gene therapy of hematological disorders: current challenges","volume":"26","author":"Al-Saif","year":"2019","journal-title":"Gene Ther"},{"key":"10.1016\/j.reth.2024.12.007_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1365-2249.2000.01359.x","article-title":"Severe combined immunodeficiencies (SCID)","volume":"122","author":"Fischer","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.reth.2024.12.007_bib3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/bjh.15831","article-title":"How I manage patients with Wiskott Aldrich syndrome","volume":"185","author":"Rivers","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.reth.2024.12.007_bib4","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s12325-017-0636-2","article-title":"A\u00a0review of chronic granulomatous disease","volume":"34","author":"Arnold","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.reth.2024.12.007_bib5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.hoc.2022.03.008","article-title":"Gene therapy for hemoglobinopathies: beta-thalassemia, sickle cell disease","volume":"36","author":"Leonard","year":"2022","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.reth.2024.12.007_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ijlh.13851","article-title":"Hemoglobinopathies and preimplantation diagnostics","volume":"44","author":"Mamas","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.reth.2024.12.007_bib7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1586\/ehm.11.39","article-title":"Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up","volume":"4","author":"Bhatia","year":"2011","journal-title":"Expert Rev Hematol"},{"issue":"21","key":"10.1016\/j.reth.2024.12.007_bib8","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1182\/bloodadvances.2022007803","article-title":"Evaluation of clonal hematopoiesis in pediatric ADA-SCID gene therapy participants","volume":"6","author":"White","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.reth.2024.12.007_bib9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3324\/haematol.2017.184788","article-title":"Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion","volume":"103","author":"Lagresle-Peyrou","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.reth.2024.12.007_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.648951","article-title":"Gene therapies for primary immune deficiencies","volume":"12","author":"Kohn","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.reth.2024.12.007_bib11","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.reth.2024.12.007_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/0022034509337480","article-title":"Gene therapy: design and prospects for craniofacial regeneration","volume":"88","author":"Scheller","year":"2009","journal-title":"J\u00a0Dent Res"},{"key":"10.1016\/j.reth.2024.12.007_bib13","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.reth.2024.12.007_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-sssociated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.reth.2024.12.007_bib15","article-title":"Viral vector-based gene therapy","volume":"24","author":"Li","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.reth.2024.12.007_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.reth.2024.12.007_bib17","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1182\/blood-2013-04-453209","article-title":"Development of gene therapy for blood disorders: an update","volume":"122","author":"Nienhuis","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.reth.2024.12.007_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/genes13081370","article-title":"Appraisal for the potential of viral and nonviral vectors in gene therapy: a review","volume":"13","author":"Butt","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.reth.2024.12.007_bib19","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.3390\/v6124811","article-title":"Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapy","volume":"6","author":"Suerth","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.reth.2024.12.007_bib20","series-title":"Periodicum biologorum","first-page":"139","article-title":"Viral vectors in gene therapy","author":"Slade","year":"2001"},{"key":"10.1016\/j.reth.2024.12.007_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in\u00a0vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.reth.2024.12.007_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A\u00a0third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.reth.2024.12.007_bib23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1042\/BJ20120146","article-title":"Lentiviral vectors: basic to translational","volume":"443","author":"Sakuma","year":"2012","journal-title":"Biochem J"},{"issue":"9","key":"10.1016\/j.reth.2024.12.007_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v12091016","article-title":"Lentiviral vector pseudotypes: precious tools to improve gene modification of hematopoietic cells for research and gene therapy","volume":"12","author":"Gutierrez-Guerrero","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.reth.2024.12.007_bib25","doi-asserted-by":"crossref","DOI":"10.2741\/2912","article-title":"Processing of adeno-associated virus RNA","volume":"13","author":"Qiu","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.reth.2024.12.007_bib26","unstructured":"Deyle DR, Russell DW. Adeno-associated virus vector integration."},{"key":"10.1016\/j.reth.2024.12.007_bib27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin Microbiol Rev"},{"issue":"15","key":"10.1016\/j.reth.2024.12.007_bib28","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in\u00a0vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.reth.2024.12.007_bib29","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1016\/j.csbj.2022.06.015","article-title":"Development and clinical translation of ex\u00a0vivo gene therapy","volume":"20","author":"Wu","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.reth.2024.12.007_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/1824-7288-36-76","article-title":"Genetics of SCID","volume":"36","author":"Cossu","year":"2010","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.reth.2024.12.007_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11061589","article-title":"Severe combined immunodeficiency\u2014classification, microbiology association and treatment","volume":"11","author":"Justiz-Vaillant","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.reth.2024.12.007_bib32","first-page":"11","article-title":"A\u00a0decade experience on severe combined immunodeficiency phenotype in Oman, bridging to newborn screening","author":"Al","year":"2021","journal-title":"Front Immunol"},{"issue":"15","key":"10.1016\/j.reth.2024.12.007_bib33","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A\u00a0modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.reth.2024.12.007_bib34","author":"Touzot"},{"issue":"335","key":"10.1016\/j.reth.2024.12.007_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.reth.2024.12.007_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31344-x","article-title":"Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency","volume":"13","author":"De Ravin","year":"2022","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.reth.2024.12.007_bib37","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1038\/sj.onc.1205428","article-title":"Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas","volume":"21","author":"Fedele","year":"2002","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.reth.2024.12.007_bib38","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1128\/JVI.74.10.4679-4687.2000","article-title":"The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites","volume":"74","author":"Rivella","year":"2000","journal-title":"J\u00a0Virol"},{"issue":"7313","key":"10.1016\/j.reth.2024.12.007_bib39","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.reth.2024.12.007_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","article-title":"Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"128","author":"Cicalese","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.reth.2024.12.007_bib41","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1172\/JCI90367","article-title":"Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency","volume":"127","author":"Shaw","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.reth.2024.12.007_bib42","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-12-756734","article-title":"Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients","volume":"129","author":"Cooper","year":"2017","journal-title":"Blood [Internet]"},{"issue":"16","key":"10.1016\/j.reth.2024.12.007_bib43","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.reth.2024.12.007_bib44","author":"Reinhardt"},{"issue":"21","key":"10.1016\/j.reth.2024.12.007_bib45","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous ex\u00a0vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.reth.2024.12.007_bib46","doi-asserted-by":"crossref","unstructured":"Cuvelier GDE, Logan BR, Prockop SE, Buckley RH, Kuo CY, Griffith LM, et\u00a0al. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC [Internet]. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/140\/7\/685\/1915098\/bloodbld2022016196.pdf.","DOI":"10.1182\/blood.2022016196"},{"issue":"25","key":"10.1016\/j.reth.2024.12.007_bib47","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa2206575","article-title":"Lentiviral gene therapy for artemis-deficient SCID","volume":"387","author":"Cowan","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6148","key":"10.1016\/j.reth.2024.12.007_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.reth.2024.12.007_bib49","unstructured":"Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, et\u00a0al. Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity [Internet]. Available from:: www.ScienceTranslationalMedicine.org."},{"issue":"3","key":"10.1016\/j.reth.2024.12.007_bib50","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jaci.2015.01.035","article-title":"B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome","volume":"136","author":"Castiello","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"15","key":"10.1016\/j.reth.2024.12.007_bib51","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA, J Am Med Assoc"},{"issue":"5","key":"10.1016\/j.reth.2024.12.007_bib52","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.reth.2024.12.007_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38448-y","article-title":"Hematopoietic reconstitution dynamics of mobilized- and bone marrow-derived human hematopoietic stem cells after gene therapy","volume":"14","author":"Scala","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.reth.2024.12.007_bib54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12016-020-08800-x","article-title":"Chronic granulomatous disease: a comprehensive review","volume":"61","author":"Yu","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.reth.2024.12.007_bib55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.reth.2024.12.007_bib56","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1073\/pnas.94.22.12133","article-title":"Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease","volume":"94","author":"Malech","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.reth.2024.12.007_bib57","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2174\/1566523215666150515145255","article-title":"Successful combination of sequential gene therapy and rescue allo-HSCT in two children with X-CGD - importance of timing","volume":"15","author":"Siler","year":"2015","journal-title":"Curr Gene Ther"},{"issue":"2","key":"10.1016\/j.reth.2024.12.007_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.100919","article-title":"Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy","volume":"4","author":"Sobrino","year":"2023","journal-title":"Cell Reports Med"},{"key":"10.1016\/j.reth.2024.12.007_bib59","unstructured":"Akbarp H, Meamar Zadeh M. Leukocyte adhesion deficiency."},{"key":"10.1016\/j.reth.2024.12.007_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/adc.69.4.463","article-title":"CURRENT TOPIC Leucocyte adhesion deficiency","volume":"69","author":"El Habbal","year":"1993","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.reth.2024.12.007_bib61","first-page":"518","article-title":"Canine leukocyte adhesion deficiency: presence of the Cys36Ser \u03b2-2 integrin mutation in an affected US Irish setter cross-breed dog and in US Irish red and white setters","volume":"16","author":"Foureman","year":"2002","journal-title":"J\u00a0Vet Intern Med"},{"key":"10.1016\/j.reth.2024.12.007_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.612703","article-title":"Clinical and genetic spectrum of a large cohort of patients with leukocyte adhesion deficiency type 1 and 3: a multicentric study from India","volume":"11","author":"Kambli","year":"2020","journal-title":"Front Immunol"},{"issue":"Supplement 1","key":"10.1016\/j.reth.2024.12.007_bib63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-142484","article-title":"A\u00a0phase 1\/2 study of lentiviral-mediated ex-vivo gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I): results from phase 1","volume":"136","author":"Kohn","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.reth.2024.12.007_bib64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tripleo.2007.02.026","article-title":"Leukocyte adhesion deficiency type 1: an important consideration in the clinical differential diagnosis of prepubertal periodontitis. A case report and review of the literature","volume":"105","author":"Cox","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"23","key":"10.1016\/j.reth.2024.12.007_bib65","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood.V126.23.202.202","article-title":"Outcomes of gene therapy for severe sickle disease and beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex\u00a0vivo with a lentiviral beta AT87Q-globin vector","volume":"126","author":"Cavazzana","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.reth.2024.12.007_bib66","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet [Internet]"},{"issue":"3","key":"10.1016\/j.reth.2024.12.007_bib67","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.reth.2024.12.007_bib68","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.reth.2024.12.007_bib69","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1182\/blood.V128.22.1176.1176","article-title":"Interim results from a phase 1\/2 clinical study of lentiglobin gene therapy for severe sickle cell disease","volume":"128","author":"Kanter","year":"2016","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.reth.2024.12.007_bib70","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.reth.2024.12.007_bib71","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1182\/bloodadvances.2020003680","article-title":"Wild-type HIV infection after treatment with lentiviral gene therapy for \u03b2-thalassemia","volume":"5","author":"Hongeng","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.reth.2024.12.007_bib72","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41591-018-0301-6","article-title":"Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent \u00df-thalassemia","volume":"25","author":"Marktel","year":"2019","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.reth.2024.12.007_bib73","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1089\/hgtb.2018.032","article-title":"The functional effect of repeated cryopreservation on transduced CD34+ cells from patients with thalassemia","volume":"29","author":"Karponi","year":"2018","journal-title":"Hum Gene Ther Methods"},{"issue":"1","key":"10.1016\/j.reth.2024.12.007_bib74","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41591-021-01554-9","article-title":"Lentiviral globin gene therapy with reduced-intensity conditioning in adults with \u03b2-thalassemia: a phase 1 trial","volume":"28","author":"Boulad","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.reth.2024.12.007_bib75","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene autotemcel gene therapy for non\u2013\u03b2 0\/\u03b2 0 genotype \u03b2-thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.reth.2024.12.007_bib76","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1089\/hum.2018.124","article-title":"Advances in gene therapy for fanconi anemia","volume":"29","author":"R\u00edo","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"15","key":"10.1016\/j.reth.2024.12.007_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158416","article-title":"Correction of fanconi anemia mutations using digital genome engineering","volume":"23","author":"Sipe","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.reth.2024.12.007_bib78","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/humc.2015.2522","article-title":"Gene therapy trial of fanconi anemia patients with a new orphan Drug consisting of a lentiviral vector carrying the FANCA gene: a coordinated international action (EuroFancolen)","volume":"26","author":"Phase","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"11","key":"10.1016\/j.reth.2024.12.007_bib79","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3324\/haematol.2018.194571","article-title":"Novel lineage depletion preserves autologous blood stem cells for gene therapy of fanconi anemia complementation group A","volume":"103","author":"Adair","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.reth.2024.12.007_bib80","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41591-019-0550-z","article-title":"Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia","volume":"25","author":"R\u00edo","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.reth.2024.12.007_bib81","unstructured":"Nathwani AC. Gene ther apy for hemophilia | Gene ther apy for hemo philia."},{"issue":"21","key":"10.1016\/j.reth.2024.12.007_bib82","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.reth.2024.12.007_bib83","series-title":"New England Journal","first-page":"2519","author":"Rangarajan","year":"2017"},{"key":"10.1016\/j.reth.2024.12.007_bib84","author":"Rosen"},{"issue":"23","key":"10.1016\/j.reth.2024.12.007_bib85","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.reth.2024.12.007_bib86","author":"Miesbach"},{"issue":"9","key":"10.1016\/j.reth.2024.12.007_bib87","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.reth.2024.12.007_bib88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.reth.2024.12.007_bib89","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.reth.2024.12.007_bib90","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.reth.2024.12.007_bib91","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.reth.2024.12.007_bib92","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.reth.2024.12.007_bib93","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.reth.2024.12.007_bib94","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.reth.2024.12.007_bib95","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with Etranacogene Dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.reth.2024.12.007_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10258","article-title":"Viral vector-based gene therapies in the clinic","volume":"7","author":"Zhao","year":"2022","journal-title":"Bioeng Transl Med"},{"issue":"11","key":"10.1016\/j.reth.2024.12.007_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13112625","article-title":"Virus-driven carcinogenesis","volume":"13","author":"Hatano","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.reth.2024.12.007_bib98","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11901-023-00624-5","article-title":"Hepatotoxicity in adeno-associated viral vector gene therapy","volume":"22","author":"Jagadisan","year":"2023","journal-title":"Curr Hepatol Reports [Internet]"},{"issue":"1","key":"10.1016\/j.reth.2024.12.007_bib99","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4525-0","article-title":"MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-\u039aB","volume":"18","author":"Cordas dos Santos","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.reth.2024.12.007_bib100","series-title":"Multiyear\u00a0follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","first-page":"29","author":"Symington","year":"2020"},{"issue":"May","key":"10.1016\/j.reth.2024.12.007_bib101","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S1525-0016(16)33088-X","article-title":"279. Clinical outcomes of gene therapy with BB305 lentiviral vector for sickle cell disease and \u03b2-thalassemia","volume":"24","author":"Cavazzana","year":"2016","journal-title":"Mol Ther"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235232042400227X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235232042400227X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T07:28:25Z","timestamp":1741505305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235232042400227X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":101,"alternative-id":["S235232042400227X"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2024.12.007","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral-based gene therapy clinical trials for immune deficiencies and blood disorders from 2013 until 2023 - an overview","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2024.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier BV on behalf of The Japanese Society for Regenerative Medicine.","name":"copyright","label":"Copyright"}]}}